tradingkey.logo
tradingkey.logo
Search

Amneal Pharmaceuticals Inc

AMRX
Add to Watchlist
17.310USD
+0.020+0.12%
Close 06/30, 16:00ETQuotes delayed by 15 min
5.52BMarket Cap
44.64P/E TTM

More Details of Amneal Pharmaceuticals Inc Company

Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.

Amneal Pharmaceuticals Inc Info

Ticker SymbolAMRX
Company nameAmneal Pharmaceuticals Inc
IPO dateNov 18, 2009
CEOPatel (Chintu)
Number of employees8100
Security typeOrdinary Share
Fiscal year-endNov 18
Address400 Crossing Boulevard, 3rd Floor
CityBRIDGEWATER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code08807
Phone19089473120
Websitehttps://amneal.com/
Ticker SymbolAMRX
IPO dateNov 18, 2009
CEOPatel (Chintu)

Company Executives of Amneal Pharmaceuticals Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Chintu Patel
Mr. Chintu Patel
Co-Chief Executive Officer, Co-Founder, Director
Co-Chief Executive Officer, Co-Founder, Director
26.14M
+2.01%
Mr. Gautam Patel
Mr. Gautam Patel
Director
Director
1.64M
+2.12%
Mr. Anastasios G. (Tasos) Konidaris
Mr. Anastasios G. (Tasos) Konidaris
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
449.43K
-38.37%
Ms. Nikita Shah
Ms. Nikita Shah
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
399.79K
+52.12%
Mr. Shlomo Yanai
Mr. Shlomo Yanai
Independent Director
Independent Director
320.80K
+10.85%
Ms. Deborah M. (Deb) Autor
Ms. Deborah M. (Deb) Autor
Independent Director
Independent Director
93.66K
--
Buchi (J Kevin)
Buchi (J Kevin)
Independent Director
Independent Director
--
--
Mr. Andrew S. Boyer
Mr. Andrew S. Boyer
Executive Vice President, Chief Commercial Officer - Generics
Executive Vice President, Chief Commercial Officer - Generics
--
--
Mr. Chirag Patel
Mr. Chirag Patel
President, Co-Chief Executive Officer, Co-Founder, Director
President, Co-Chief Executive Officer, Co-Founder, Director
--
--
Mr. Ted Nark
Mr. Ted Nark
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Chintu Patel
Mr. Chintu Patel
Co-Chief Executive Officer, Co-Founder, Director
Co-Chief Executive Officer, Co-Founder, Director
26.14M
+2.01%
Mr. Gautam Patel
Mr. Gautam Patel
Director
Director
1.64M
+2.12%
Mr. Anastasios G. (Tasos) Konidaris
Mr. Anastasios G. (Tasos) Konidaris
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
449.43K
-38.37%
Ms. Nikita Shah
Ms. Nikita Shah
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
399.79K
+52.12%
Mr. Shlomo Yanai
Mr. Shlomo Yanai
Independent Director
Independent Director
320.80K
+10.85%
Ms. Deborah M. (Deb) Autor
Ms. Deborah M. (Deb) Autor
Independent Director
Independent Director
93.66K
--

FAQs

Who are the top five shareholders of Amneal Pharmaceuticals Inc?

The top five shareholders of Amneal Pharmaceuticals Inc are: Mr. Chintu Patel

How many institutions hold shares of Amneal Pharmaceuticals Inc (AMRX)?

As of 2026Q1, 521 institutions hold shares of Amneal Pharmaceuticals Inc, with a combined market value of approximately 161.64M, accounting for 50.67% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -25718515.00.

What is the biggest source of revenue for Amneal Pharmaceuticals Inc?

In 2026Q1, the Oral solid business generated the highest revenue for Amneal Pharmaceuticals Inc, amounting to 726.38M and accounting for 24.06% of total revenue.
KeyAI